Hap Trading, LLC Viking Therapeutics, Inc. Call Options Transaction History

Hap Trading, LLC

16 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$47.39 - $80.2 $4.03 Million - $6.82 Million	-85,000 Reduced 34.0%	165,000 $21.6 Million
Q1 2024 May 13, 2024	BUY	$17.4 - $94.5 $4.35 Million - $23.6 Million	250,000 New	250,000 $491 Million
Q4 2022 Feb 14, 2023	SELL	$2.72 - $9.4 $3,808 - $13,160	-1,400 Reduced 3.28%	41,300 $140,000
Q3 2022 Nov 14, 2022	BUY	$2.55 - $3.89 $9,945 - $15,171	3,900 Added 10.05%	42,700 $7,000
Q2 2022 Aug 12, 2022	SELL	$2.11 - $3.15 $9,706 - $14,490	-4,600 Reduced 10.6%	38,800 $12,000
Q1 2022 May 12, 2022	BUY	$3.0 - $4.88 $84,300 - $137,128	28,100 Added 183.66%	43,400 $19,000
Q4 2021 Feb 14, 2022	SELL	$4.6 - $6.72 $10,580 - $15,456	-2,300 Reduced 13.07%	15,300 $7,000
Q3 2021 Nov 10, 2021	BUY	$5.58 - $7.04 $98,208 - $123,904	17,600 New	17,600 $6,000
Q1 2021 May 14, 2021	SELL	$5.74 - $9.67 $101,598 - $171,159	-17,700 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$5.3 - $6.71 $93,810 - $118,767	17,700 New	17,700 $0
Q3 2019 Nov 12, 2019	SELL	$6.55 - $8.6 $76,635 - $100,620	-11,700 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$7.67 - $10.63 $266,149 - $368,861	-34,700 Reduced 74.78%	11,700 $3,000
Q1 2019 May 10, 2019	BUY	$7.58 - $9.94 $253,172 - $331,996	33,400 Added 256.92%	46,400 $58,000
Q4 2018 Feb 12, 2019	BUY	$7.16 - $16.21 $93,080 - $210,730	13,000 New	13,000 $8,000
Q3 2018 Nov 09, 2018	SELL	$9.7 - $19.65 $157,140 - $318,330	-16,200 Closed	0 $0
Q2 2018 Aug 13, 2018	BUY	$3.88 - $12.74 $62,856 - $206,388	16,200 New	16,200 $38,000

474

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.18B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.